The major objective of this study is to determine if intravenous immunoglobulin (IVIG) is an effective therapy for myasthenia gravis. This will be established by performing a double blind, placebo controlled study in which myasthenia patients receive either IVIG or albumin. Many myasthenia are already being treated with IVIG on the basis of annectodatal evidence; this will be the first placebo controlled study to determine whether IVIG does in fact improve symptoms, signs, or electrophysiologic and laboratory parameters of autoimmune dysfunction in MG.
Showing the most recent 10 out of 600 publications